Abstract
See related article, pages 1770–1773 . Intravenous thrombolysis has become generally accepted and is currently the only FDA approved medical therapy for treatment of patients with acute ischemic stroke. Its use is associated with improved outcomes of patients who can be treated within 3 hours of stroke onset.1 A higher concentration of thrombolytic agents delivered directly into the thrombus has led to the promotion of intra-arterial thrombolysis, although the possible clinical benefits may be counterbalanced by delays to initiating treatment.2,3 With the evolving concept of interventional management of stroke, several options of multimodal reperfusion therapy are being evaluated. Options include emergency angioplasty and stenting as well as mechanical disruption or extraction of the thrombus.4–6 …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
